Scholarlink

<p>This retrospective study explored the use of different cut-off values for serum thyroglobulin antibody (TgAb) to judge the outcomes of <sup>131</sup>I for papillary thyroid microcarcinoma (PTMC). After <sup>131</sup>I therapy and TSH suppression, excellent response rates (ERRs) increased over time by both TgAb standards (TgAb &lt; 10.0 KIU/L and TgAb &lt; 115.0 KIU/L) but were significantly higher using the manufacturer cut-off (6.7 versus 22.2%, at 1&#xa0;month; 8.9 versus 42.2%, at 4&#xa0;months; 13.3 versus 48.9%, at 10&#xa0;months; <i>p</i> &lt; 0.01). Hence, the positive rate and ERR of TgAb in PTMC patients were significantly effectuated by the adopted cut-off value.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The dynamic evaluation of 131I therapy response in papillary thyroid microcarcinoma patients

  • 期刊论文

  • 发表日期：

    2025年5月22日

查看全文
  • Fengling Shan,
  • Bingbing Pu,
  • Yu Zhang,
  • Xingdang Liu,
  • Shuai Xue,
  • Jingjing Lou,
  • Chentian Shen

摘要

This retrospective study explored the use of different cut-off values for serum thyroglobulin antibody (TgAb) to judge the outcomes of 131I for papillary thyroid microcarcinoma (PTMC). After 131I therapy and TSH suppression, excellent response rates (ERRs) increased over time by both TgAb standards (TgAb < 10.0 KIU/L and TgAb < 115.0 KIU/L) but were significantly higher using the manufacturer cut-off (6.7 versus 22.2%, at 1 month; 8.9 versus 42.2%, at 4 months; 13.3 versus 48.9%, at 10 months; p < 0.01). Hence, the positive rate and ERR of TgAb in PTMC patients were significantly effectuated by the adopted cut-off value.